Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide (original) (raw)

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer in humans, and although metastasis rarely occurs, the tumor cells are nevertheless able to invade and destroy the surrounding tissue. Intralesional injection of IFN-alpha has been found to be highly effective in inducing BCC regression by an unknown mechanism. We show that in untreated patients, BCC cells express CD95 ligand, but not the receptor, which may allow tumor expansion by averting the attack of activated CD95 receptor-positive lymphoid effector cells. The CD95 ligand of BCC cells is functional as CD95-positive cells incubated on BCC cryosections become apoptotic and are lysed. In IFN-alpha-treated patients BCC cells express not only CD95 ligand but also CD95 receptor, whereas the peritumoral infiltrate that mainly consists of CD4+ T cells predominantly contains CD95 receptor and only few CD95 ligand-positive cells. Thus, in treated patients BCC most likely regresses by committing suicide through apoptosis induction via CD95 receptor-CD95 ligand interaction.

Full Text

The Full Text of this article is available as a PDF (361.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R. C. A role for CD95 ligand in preventing graft rejection. Nature. 1995 Oct 19;377(6550):630–632. doi: 10.1038/377630a0. [DOI] [PubMed] [Google Scholar]
  2. Brinkmann V., Geiger T., Alkan S., Heusser C. H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993 Nov 1;178(5):1655–1663. doi: 10.1084/jem.178.5.1655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Buechner S. A. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol. 1991 May;24(5 Pt 1):731–734. doi: 10.1016/0190-9622(91)70111-e. [DOI] [PubMed] [Google Scholar]
  4. Buja L. M., Eigenbrodt M. L., Eigenbrodt E. H. Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch Pathol Lab Med. 1993 Dec;117(12):1208–1214. [PubMed] [Google Scholar]
  5. Chimenti S., Peris K., Di Cristofaro S., Fargnoli M. C., Torlone G. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology. 1995;190(3):214–217. doi: 10.1159/000246688. [DOI] [PubMed] [Google Scholar]
  6. Cornell R. C., Greenway H. T., Tucker S. B., Edwards L., Ashworth S., Vance J. C., Tanner D. J., Taylor E. L., Smiles K. A., Peets E. A. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694–700. doi: 10.1016/0190-9622(90)70276-n. [DOI] [PubMed] [Google Scholar]
  7. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996 May;2(5):574–577. doi: 10.1038/nm0596-574. [DOI] [PubMed] [Google Scholar]
  8. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. doi: 10.1083/jcb.119.3.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Golstein P., Ojcius D. M., Young J. D. Cell death mechanisms and the immune system. Immunol Rev. 1991 Jun;121:29–65. doi: 10.1111/j.1600-065x.1991.tb00822.x. [DOI] [PubMed] [Google Scholar]
  10. Greenway H. T., Cornell R. C., Tanner D. J., Peets E., Bordin G. M., Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 1986 Sep;15(3):437–443. doi: 10.1016/s0190-9622(86)70192-8. [DOI] [PubMed] [Google Scholar]
  11. Gresser I. Biologic effects of interferons. J Invest Dermatol. 1990 Dec;95(6 Suppl):66S–71S. doi: 10.1111/1523-1747.ep12874776. [DOI] [PubMed] [Google Scholar]
  12. Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995 Nov 17;270(5239):1189–1192. doi: 10.1126/science.270.5239.1189. [DOI] [PubMed] [Google Scholar]
  13. Grob J. J., Collet A. M., Munoz M. H., Bonerandi J. J. Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a. Lancet. 1988 Apr 16;1(8590):878–879. doi: 10.1016/s0140-6736(88)91620-0. [DOI] [PubMed] [Google Scholar]
  14. Hahn S., Gehri R., Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev. 1995 Aug;146:57–79. doi: 10.1111/j.1600-065x.1995.tb00684.x. [DOI] [PubMed] [Google Scholar]
  15. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  16. Hanabuchi S., Koyanagi M., Kawasaki A., Shinohara N., Matsuzawa A., Nishimura Y., Kobayashi Y., Yonehara S., Yagita H., Okumura K. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4930–4934. doi: 10.1073/pnas.91.11.4930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hunt M. J., Halliday G. M., Weedon D., Cooke B. E., Barnetson R. S. Regression in basal cell carcinoma: an immunohistochemical analysis. Br J Dermatol. 1994 Jan;130(1):1–8. doi: 10.1111/j.1365-2133.1994.tb06873.x. [DOI] [PubMed] [Google Scholar]
  18. Ju S. T., Cui H., Panka D. J., Ettinger R., Marshak-Rothstein A. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4185–4189. doi: 10.1073/pnas.91.10.4185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kerr J. F., Winterford C. M., Harmon B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994 Apr 15;73(8):2013–2026. doi: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  20. Knop J. Immunologic effects of interferon. J Invest Dermatol. 1990 Dec;95(6 Suppl):72S–74S. doi: 10.1111/1523-1747.ep12874780. [DOI] [PubMed] [Google Scholar]
  21. Leithäuser F., Dhein J., Mechtersheimer G., Koretz K., Brüderlein S., Henne C., Schmidt A., Debatin K. M., Krammer P. H., Möller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993 Oct;69(4):415–429. [PubMed] [Google Scholar]
  22. Lenardo M. J. Fas and the art of lymphocyte maintenance. J Exp Med. 1996 Mar 1;183(3):721–724. doi: 10.1084/jem.183.3.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mozzanica N., Cattaneo A., Boneschi V., Brambilla L., Melotti E., Finzi A. F. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Arch Dermatol Res. 1990;282(5):311–317. doi: 10.1007/BF00375725. [DOI] [PubMed] [Google Scholar]
  24. Nagata S., Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449–1456. doi: 10.1126/science.7533326. [DOI] [PubMed] [Google Scholar]
  25. Nicoletti I., Migliorati G., Pagliacci M. C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991 Jun 3;139(2):271–279. doi: 10.1016/0022-1759(91)90198-o. [DOI] [PubMed] [Google Scholar]
  26. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996 Sep 1;184(3):1075–1082. doi: 10.1084/jem.184.3.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Oishi M., Maeda K., Sugiyama S. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res. 1994;286(7):396–407. doi: 10.1007/BF00371800. [DOI] [PubMed] [Google Scholar]
  28. Rodríguez-Villanueva J., McDonnell T. J. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int J Cancer. 1995 Mar 29;61(1):110–114. doi: 10.1002/ijc.2910610119. [DOI] [PubMed] [Google Scholar]
  29. Saas P., Walker P. R., Hahne M., Quiquerez A. L., Schnuriger V., Perrin G., French L., Van Meir E. G., de Tribolet N., Tschopp J. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997 Mar 15;99(6):1173–1178. doi: 10.1172/JCI119273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sayama K., Yonehara S., Watanabe Y., Miki Y. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol. 1994 Sep;103(3):330–334. doi: 10.1111/1523-1747.ep12394858. [DOI] [PubMed] [Google Scholar]
  31. Stalder T., Hahn S., Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol. 1994 Feb 1;152(3):1127–1133. [PubMed] [Google Scholar]
  32. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  33. Takahashi H., Kobayashi H., Hashimoto Y., Matsuo S., Iizuka H. Interferon-gamma-dependent stimulation of Fas antigen in SV40-transformed human keratinocytes: modulation of the apoptotic process by protein kinase C. J Invest Dermatol. 1995 Dec;105(6):810–815. doi: 10.1111/1523-1747.ep12326577. [DOI] [PubMed] [Google Scholar]
  34. Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S. Fas ligand in human serum. Nat Med. 1996 Mar;2(3):317–322. doi: 10.1038/nm0396-317. [DOI] [PubMed] [Google Scholar]
  35. Tanaka M., Suda T., Takahashi T., Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 1995 Mar 15;14(6):1129–1135. doi: 10.1002/j.1460-2075.1995.tb07096.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Thestrup-Pedersen K., Jacobsen I. E., Frentz G. Intralesional interferon-alpha 2b treatment of basal cell carcinoma. Acta Derm Venereol. 1990;70(6):512–514. [PubMed] [Google Scholar]
  37. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science. 1995 Mar 10;267(5203):1456–1462. doi: 10.1126/science.7878464. [DOI] [PubMed] [Google Scholar]
  38. Tong Y., Tucker S. B. Normal human skin lymphocytic and Langerhans' cell responses to intradermal interferon alpha-2 beta injections. Am J Med Sci. 1993 Jul;306(1):23–27. doi: 10.1097/00000441-199307000-00007. [DOI] [PubMed] [Google Scholar]
  39. Ucar R., Sanwo M., Ucar K., Beall G. Interferons: their role in clinical practice. Ann Allergy Asthma Immunol. 1995 Nov;75(5):377–389. [PubMed] [Google Scholar]
  40. Ueda N., Shah S. V. Apoptosis. J Lab Clin Med. 1994 Aug;124(2):169–177. [PubMed] [Google Scholar]
  41. Wickramasinghe L., Hindson T. C., Wacks H. Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol. 1989 Jan;20(1):71–74. doi: 10.1016/s0190-9622(89)70009-8. [DOI] [PubMed] [Google Scholar]
  42. Williams G. T. Apoptosis in the immune system. J Pathol. 1994 May;173(1):1–4. doi: 10.1002/path.1711730102. [DOI] [PubMed] [Google Scholar]
  43. Wyllie A. H., Kerr J. F., Currie A. R. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306. doi: 10.1016/s0074-7696(08)62312-8. [DOI] [PubMed] [Google Scholar]